[1] Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1- patients with End-Stage Renal Disease on hemodialysis or GFR <30mL/min. Liver Int,2016,36:798-801.
[2] Singh T, Guirguis J, Anthony S, et al. Sofosbuvir based treatment is safe and effective in patients with chronic hepatitis C infection and end-stage renal disease: a case series. Liver Int,2016, 36:802-806.
[3] Desnoyer A, Pospai D, Le MP, et al.Sofosbuvir-containing regimen for HCV infection in hemodialysis patients:400 mg daily or only on the day of hemodialysis. J Hepatol,2016,65:40-47.
[4] Wanchoo R, Thakkar J, Schwartz D, et al. Harvoni (Ledipasvir With Sofosbuvir)-induced renal injury. Am J Gastroenterol,2016,111:148-149.
[5] Welker MW, Luhne S, Lange CM, et al. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol,2016,64:790-799. |
